Rocket Pharmaceuticals (NASDAQ: RCKT)
Rocket Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Rocket Pharmaceuticals Company Info
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
News & Analysis
Rocket (RCKT) Q2 Loss Narrows 16%
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully
Its near-term risks are subtle but bigger than their flying stock price might indicate.
Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy.
Biotech’s Year-End To-Do List
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.